Home / Prostate Reference Lab Testing Services / Document

Prostate Cancer Genomic Classifier Sources Sought

Updated

A PDF document (97 KB) attached to Prostate Reference Lab Testing Services, from the Department of Veterans Affairs. Due Nov 25, 2026, 4:00 PM (UTC-5).

File name: Prostate_Cancer_Genomic_Classifier_Sources_Sought.pdf

Download the full documentSee the bid

The full file is for paid members, or buy this bid alone.

Preview

SOURCES SOUGHT NOTICE

Prostate Cancer Genomic Classifier Testing Services

THIS IS NOT A SOLICITATION

This is a Sources Sought Notice only. It is issued solely for information and planning purposes and does not constitute a solicitation. This notice is issued in accordance with Federal Acquisition Regulation (FAR) Part 10, Market Research.
The Department of Veterans Affairs (VA) is conducting market research to identify qualified sources capable of providing prostate cancer genomic classifier testing services. The purpose of this notice is to determine the availability of capable businesses and inform an appropriate acquisition strategy. This notice shall not be construed as a commitment by the Government to issue a solicitation or award a contract. Responses are not offers and cannot be accepted by the Government to form a binding contract. The Government will not reimburse any costs associated with responding to this notice.

Agency Information
Agency

Department of Veterans Affairs, Veterans Health Administration

Contracting Office

Network Contracting Office (NCO) 10, Ohio, Columbus VAAC

NAICS Code

621511 - Medical Laboratories

Product Service Code

Q301 - Medical Laboratory Testing

Requirement Description
The Department of Veterans Affairs requires genomic testing services to support clinical decision-making for Veterans diagnosed with prostate cancer.
The required services shall analyze tissue specimens obtained from prostate biopsy and/or prostatectomy procedures and provide clinically actionable genomic information to assist treating physicians in assessing disease aggressiveness, risk of disease progression, risk of metastasis, and prostate cancer-specific mortality.
The resulting clinical report shall provide information that may assist healthcare providers in evaluating treatment options, including:
•
•
•
•
•
•

Active surveillance
Definitive treatment planning
Radiation therapy decision-making
Post-prostatectomy management
Risk stratification
Treatment intensification considerations

The Government is seeking information from vendors capable of providing commercially available genomic classifier testing services that support personalized treatment decision-making for patients diagnosed with localized, recurrent, or advanced prostate cancer.

Minimum Capabilities
1. Receipt and accessioning of prostate tissue specimens collected at VA medical facilities. 2. Genomic analysis utilizing a validated molecular testing platform.

The beginning of the document. Download the full file to read on.

Other documents in this bid